Pages

Sunday, January 31, 2021

Fw: (LML) New Face for Leprosy

 


Leprosy Mailing List – January 31,  2021

 

Ref.:  (LML) New Face for Leprosy

 

From:  Diana Lockwood, London, UK

 

 

Dear Pieter,

 

The New Face for Leprosy website will go live on World Leprosy Day Jan 31 2021. https://newfaceleprosy.com/  The New Face team hope to reduce the stigma associated with leprosy by showing people affected by leprosy leading normal lives with jobs, families and interests. The people have a message of hope " do not despair, leprosy is not hereditary. You should see my beautiful grandchildren".

The photographs and stories of people in Ethiopia and India have been published, we have given lectures and exhibited photos in London supported by Lepra.

We shall post more stories and photos on the website.  The project will be expanded to other countries in the future.  We thank Lepra UK for supporting this project.  

 

Diana Lockwood 

Tom Bradley  

Saba Lambert 

 

Best wishes,

Diana

 

Diana NJ Lockwood

Emeritus professor of Tropical Medicine

London School of Hygiene & Tropical Medicine

Keppel St

London WC1E 7HT

Visit my blog http://dnjtravels.blogspot.co.uk/

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/59e14f3a-4d87-4646-83e4-04134811026en%40googlegroups.com.

Fw: (LML) World Leprosy Day

 

 

 

Leprosy Mailing List – January 31,  2021

 

Ref.:  (LML) World Leprosy Day

 

From:  Alice Cruz, Quito, Ecuador

 

Dear Pieter,

 

World Leprosy Day

31 January 2021

 

From leprosy to COVID-19, we must eliminate double standards and put those furthest behind at centre of recovery: UN expert

GENEVA (28 January 2021) – A United Nations human rights expert said today that the response to the COVID-19 pandemic has failed persons affected by both leprosy and "double standards". Alice Cruz, the Special Rapporteur on the elimination of discrimination against persons affected by leprosy and their family members, made the following statement to mark World Leprosy Day on 31 January:

"We should learn from the history of leprosy. To better fight against an epidemic or a pandemic, we must eliminate discrimination and double standards for those who have been systematically left behind.

The world witnessed the massive negative impacts of COVID-19 and the crisis it generated: from deprivation of rights to family life, education, housing, employment, to domestic and sexual violence. Sadly, this is what persons affected by leprosy (also known as Hansen's disease) have been experiencing for thousands of years. Countless persons with leprosy were isolated from societies, even though there was never evidence to back up such policies. Their children were separated from parents, and often institutionalised. And till today, they remain forgotten, without reparations or a vaccine.

Since the outbreak of COVID-19, I have been receiving numerous reports on a disproportionately negative impact on persons affected by leprosy in many countries, about which I wrote an open letter to the governments. Relevant data on the humanitarian and health crisis is not even collected or made available. In the face of the lack of responses from governments, persons affected by leprosy have been at the forefront of the emergency aid to their communities. We can surely expect rising disparities and a setback in leprosy control, transmission and prevention of disabilities, as well as in the worsening of an already extremely precarious standard of living.

These double standards in the response to the COVID-19 crisis, together with the multiple menace of mutually exacerbating problems, have been threatening the right to life of persons affected by leprosy. It is deeply disturbing that since mid-2020, persons who have been diagnosed with leprosy have not received essential drugs, (namely multidrug therapy – MDT –, which is distributed free of charge) to treat the disease, in some countries, including Brazil. According to WHO data, Brazil is the country with the highest infection rates per 100,000 inhabitants (about 28,000 new cases a year) and with a significant number of people being diagnosed with already irreversible physical impairments.

Physical impairments caused by leprosy are preventable with timely diagnosis and adequate treatment with MDT. Leprosy is curable with MDT and once treatment is started the disease can no longer be transmitted. However, double standards in institutional responses to leprosy and stigmatisation associated with the disease are a barrier to ending transmission. Shortage of MDT is aggravating both disabilities and transmission and causing great suffering.

The history of leprosy shows how costly discrimination and inequalities can be, not only to individual patients, their family members, but also to societies as a whole. Several of the violations and intersections well known by persons affected by leprosy – society's fear, stigmatisation, isolation and its impact of mental health, segregation, gender-based violence, racism, xenophobia, among others – are being uncovered by the current pandemic. There is much to learn from the history of the struggle of persons affected by leprosy against all these forms of violence and discrimination. And the main lesson is that there is no building back better if States fail to put those left behind at the centre of recovery."

ENDS

Ms Alice Cruz is the UN Special Rapporteur on the elimination of discrimination against persons affected by leprosy and their family members. She was appointed in November 2017 by the Human Rights Council. Ms. Cruz worked as External Professor at the Law School of University Andina Simón Bolívar – Ecuador and in several Portuguese universities as researcher on health and human rights, in particular leprosy. She participated in the elaboration of WHO Guidelines for Strengthening Participation of Persons Affected by Leprosy in Leprosy Services. She has researched and written on the subject of eliminating leprosy and the stigma attached to it and has interacted with various stakeholders, including persons affected by leprosy.

The Special Rapporteurs are part of what is known as the Special Procedures of the Human Rights Council. Special Procedures, the largest body of independent experts in the UN Human Rights system, is the general name of the Council's independent fact-finding and monitoring mechanisms that address either specific country situations or thematic issues in all parts of the world. Special Procedures experts work on a voluntary basis; they are not UN staff and do not receive a salary for their work. They are independent from any government or organization and serve in their individual capacity.

For inquiries and media requests, please contact: Ms. Younkyo Ahn ( + 41  22 917 9537 / yahn@ohchr.org)

For media inquiries related to other UN independent experts
please contact Renato de Souza (+41 22 928 9855 rrosariodesouza@ohchr.org)

Follow the UN's independent human rights experts on Twitter @UN_SPExperts

Concerned about the world we live in?
Then STAND UP for someone's rights today.
#Standup4humanrights
and visit the web page at 
http://www.standup4humanrights.org

 

Da hanseníase à COVID-19, devemos eliminar critérios duplos e colocar aqueles que foram deixados para trás no centro da recuperação: especialista da ONU

GENEBRA (28 de janeiro de 2021) – Uma especialista em direitos humanos das Nações Unidas disse hoje que a resposta à pandemia de COVID-19 falhou com as pessoas afetadas pela hanseníase e com os "critérios duplos". Alice Cruz, Relatora Especial para a eliminação da discriminação contra as pessoas afetadas pela hanseníase e seus familiares, fez a seguinte declaração para marcar o Dia Mundial da Hanseníase em 31 de janeiro:

 

"Deveríamos aprender com a história da hanseníase. Para combater melhor uma epidemia ou uma pandemia, devemos eliminar a discriminação e os critérios duplos para aqueles que foram sistematicamente deixados para trás.

O mundo testemunhou os enormes impactos negativos da COVID-19 e a crise que esta gerou: desde a privação de direitos à vida familiar, educação, moradia, emprego, até a violência doméstica e sexual. Infelizmente, é isso que as pessoas afetadas pela hanseníase (também conhecida como doença de Hansen) têm vivenciado há milhares de anos. Inúmeras pessoas com hanseníase foram isoladas das sociedades, embora nunca tenha havido evidências para apoiar tais políticas. Seus filhos foram separados dos pais e muitas vezes institucionalizados. E até hoje, permanecem esquecidos, sem reparações ou uma vacina.

Desde o início do surto da COVID-19, tenho recebido inúmeros relatórios sobre um impacto desproporcionalmente negativo sobre as pessoas afetadas pela hanseníase em muitos países, sobre os quais escrevi em uma carta aberta aos governos. Dados relevantes sobre a crise humanitária e de saúde sequer são coletados ou disponibilizados. Diante da falta de respostas dos governos, as pessoas afetadas pela hanseníase estiveram na linha de frente da ajuda emergencial às suas comunidades. Certamente podemos esperar disparidades crescentes e um retrocesso no controle e transmissão da hanseníase e na prevenção de deficiências, bem como uma piora de um padrão de vida já extremamente precarizado.

Esses critérios duplos na resposta à crise da COVID-19, juntamente com a ameaça múltipla de problemas mutuamente exacerbados, vêm ameaçando o direito à vida das pessoas afetadas pela hanseníase. É profundamente preocupante que, desde meados de 2020, as pessoas que foram diagnosticadas com hanseníase não tenham recebido medicamentos essenciais, (ou seja, a multidrogaterapia – MDT ou PQT –, que é distribuída gratuitamente) para tratar a doença, em alguns países, inclusive no Brasil. De acordo com os dados da OMS, o Brasil é o país com as maiores taxas de infecção por 100.000 habitantes (cerca de 28.000 novos casos por ano) e com um número significativo de pessoas sendo diagnosticadas com prejuízos físicos já irreversíveis.

Os prejuízos físicos causados pela hanseníase são evitáveis com o diagnóstico oportuno e tratamento adequado com MDT. A hanseníase é curável com MDT e uma vez iniciado o tratamento a doença não pode mais ser transmitida. No entanto, critérios duplos nas respostas institucionais à hanseníase e à estigmatização associados à doença são uma barreira para o fim da transmissão. A escassez de MDT está agravando tanto as deficiências quanto a transmissão e vem causando grande sofrimento.

A história da hanseníase mostra o quanto a discriminação e as desigualdades podem ser custosas, não apenas para os pacientes e seus familiares, mas também para as sociedades como um todo. Várias das violações e intersecções bem conhecidas pelas pessoas afetadas pela hanseníase – o medo da sociedade, a estigmatização, o isolamento e seu impacto na saúde mental, segregação, violência de gênero, racismo, xenofobia, entre outras – estão vindo à tona com a pandemia atual. Há muito a aprender com a história da luta das pessoas afetadas pela hanseníase contra todas essas formas de violência e discriminação. E a principal lição é que não há nenhuma reconstrução melhor se os Estados não conseguem colocar aqueles deixados para trás no centro da recuperação."

FIM

A Sra. Alice Cruz é a Relatora Especial da ONU sobre a eliminação da discriminação contra as pessoas afetadas pela hanseníase e seus familiares. Ela foi nomeada em novembro de 2017 pelo Conselho de Direitos Humanos. A Sra. Cruz trabalhou como Professora Externa na Faculdade de Direito da Universidade Andina Simón Bolívar – Equador e em várias universidades portuguesas como pesquisadora em saúde e direitos humanos, em especial sobre a hanseníase. Participou da elaboração das Diretrizes da OMS para o Fortalecimento da Participação das Pessoas Afetadas pela Hanseníase nos Serviços da Hanseníase. Pesquisou e escreveu sobre o tema da eliminação da hanseníase e do estigma ligado a ela e interagiu com várias partes interessadas, incluindo as pessoas afetadas pela hanseníase.

Os Relatores Especiais são parte do que é conhecido como Procedimentos Especiais do Conselho de Direitos Humanos. Procedimentos Especiais, o maior órgão de especialistas independentes do sistema de Direitos Humanos da ONU, é o nome geral dos mecanismos independentes de apuração e monitoramento de fatos do Conselho que abordam situações específicas do país ou questões temáticas em todas as partes do mundo. Especialistas em Procedimentos Especiais trabalham de forma voluntária; eles não são funcionários da ONU e não recebem um salário por seu trabalho. São independentes de qualquer governo ou organização e servem em sua capacidade individual.

 

 

De la lèpre au COVID-19, nous devons éliminer la règle des deux poids, deux mesures et placer ceux qui sont laissés pour compte au centre du rétablissement: expert des Nations Unies

GENÈVE (28 janvier 2021) – L'expert des droits de l'homme des Nations Unies a déclaré aujourd'hui que la réponse à la pandémie de COVID-19 a failli vis-à-vis des personnes souffrant à la fois de la lèpre et de « deux poids, deux mesures ». Alice Cruz, la Rapporteuse Spéciale sur l'élimination de la discrimination à l'égard des personnes touchées par la lèpre et des membres de leur famille, a fait la déclaration suivante pour marquer la Journée Mondiale des Malades de la Lèpre, le 31 janvier :

 

« Nous aurions dû tirer les leçons de l'histoire de la lèpre. Pour mieux combattre une épidémie ou une pandémie, nous devons éliminer la discrimination et les deux poids, deux mesures envers ceux qui ont été systématiquement laissés pour compte.

Le monde a été témoin des impacts négatifs massifs du COVID-19 et de la crise qu'il a généré : depuis la privation des droits à une vie de famille, l'éducation, le logement, l'emploi, jusqu'à la violence domestique et sexuelle. Malheureusement, c'est ce que les personnes touchées par la lèpre (également connue sous le nom de maladie de Hansen) ont subi depuis des milliers d'années. D'innombrables personnes touchées par la lèpre ont été isolées des sociétés,  même si rien ne justifiait de telles mesures. Les enfants étaient séparés de leurs parents, et souvent placés dans des institutions. Et jusqu'à aujourd'hui, ils restent des oubliés, sans réparation ni vaccin.

Depuis le déclenchement du COVID-19, j'ai reçu de nombreux rapports concernant un impact disproportionnellement négatif sur des personnes touchées par la lèpre dans beaucoup de pays, à propos duquel j'ai écrit une lettre ouverte aux gouvernements. Des données pertinentes sur la crise humanitaire et sanitaire ne sont même pas encore collectées ou mises à disposition. Face au manque de réponses en provenance des gouvernements, des personnes touchées par la lèpre ont été en première ligne de l'aide d'urgence envers leurs communautés. On peut certainement s'attendre à des disparités croissantes et à un recul dans le contrôle de la lèpre, la transmission et la prévention des infirmités, de même qu'à une détérioration d'une qualité de vie déjà extrêmement précaire.

Ces deux poids, deux mesures dans la réponse à la crise du COVID-19, associés à la menace multiple de problèmes s'exacerbant mutuellement, ont menacé le droit de vivre des personnes touchées par la lèpre. Il est extrêmement perturbant que depuis mi-2020, des personnes chez qui la lèpre a été diagnostiquée n'ont pas reçu les médicaments essentiels, (nommément la polychimiothérapie – PCT –, qui est administrée gratuitement) pour traiter la maladie, dans certains pays, y compris le Brésil. Selon WHO data, le Brésil est le pays avec le taux d'infection par 100 000 habitants le plus élevé (autour de 28 000 nouveaux cas par an) et avec un nombre significatif de personnes diagnostiquées avec des handicaps physiques déjà irréversibles.

Les handicapsphysiques causées par la lèpre peuvent être prévenues grâce à un diagnostic précoce et à un traitement adéquat avec la PCT et, à partir du moment où le traitement débute, la maladie n'est plus transmissible. Cependant, les deux poids, deux mesures au niveau des réponses institutionnelles à la lèpre et la stigmatisation associée à la maladie constituent un obstacle à la cessation de la transmission. La pénurie de PCT aggrave à la fois les handicaps et la transmission et provoque une grande souffrance.

L'histoire de la lèpre démontre à quel point la discrimination et les inégalités peuvent s'avérer coûteuses, non seulement pour les patients individuels et les membres de leurs familles, mais également pour l'ensemble de la société. Plusieurs des violations et intersections bien connues par les personnes touchées par la lèpre – la peur de la société, la stigmatisation, l'isolement et son impact sur la santé mentale, la ségrégation, la violence basée sur le genre, le racisme, la xénophobie, parmi d'autres – sont révélées par la pandémie actuelle. Il y a beaucoup à apprendre du combat des personnes touchées par la lèpre contre toutes ces formes de violence et de discrimination. Et la leçon principale est qu'il n'y a pas de reconstruction en mieux si les États échouent à placer les laissés pour compte au centre du rétablissement. »

FIN

Mme Alice Cruz est la Rapporteuse spéciale des Nations Unies sur l'élimination de la discrimination à l'égard des personnes touchées par la lèpre et des membres de leur famille. Elle a été nommée en novembre 2017 par le Conseil des Droits de l'Homme. Mme Cruz a travaillé comme Professeure externe à la faculté de droit de l'Université Andina Simón Bolívar - Équateur et dans plusieurs universités portugaises en tant que chercheuse sur la santé et les droits de l'homme, en particulier liés à la lèpre. Elle a participé à l'élaboration des Directives de l'OMS pour le renforcement de la participation des personnes touchées par la lèpre aux services anti-lèpre. Elle a effectué des recherches et écrit sur le thème de l'élimination de la lèpre et de la stigmatisation qui y est attachée et a interagi avec diverses parties prenantes, y compris des personnes touchées par la lèpre.

Les rapporteurs spéciaux font partie des Procédures Spéciales du Conseil des droits de l'Homme. Procédures Spéciales, le plus grand corps d'experts indépendants dans le système des Droits de l'Homme des Nations Unies, est le nom général des mécanismes indépendants d'enquête et de surveillance du Conseil qui  concernent des situations nationales spécifiques ou des sujets thématiques dans toutes les parties du monde. Les experts des Procédures Spéciales travaillent sur une base volontaire ; ils ne sont pas fonctionnaires des Nations Unies  et ne reçoivent pas de salaire pour leur travail. Ils sont indépendants de tout gouvernement ou organisation et servent à titre individuel.

 

 

Desde la enfermedad de Hansen hasta COVID-19, debemos eliminar el doble criterio y poner a los más alejados en el centro de la recuperación: experta de la ONU

GINEBRA (28 de enero de 2021) – Una experta de las Naciones Unidas en derechos humanos dijo hoy que la respuesta a la pandemia COVID-19 ha fallado en las personas afectadas tanto por la enfermedad de Hansen como por el "doble criterio". Alice Cruz, Relatora Especial sobre la eliminación de la discriminación contra las personas afectadas por la lepra (enfermedad de Hansen) y sus familiares, hizo la siguiente declaración con motivo del Día Mundial de la Enfermedad de Hansen el 31 de enero:

 

"Deberíamos aprender de la historia de la enfermedad de Hansen. Para luchar mejor contra una epidemia o una pandemia, debemos eliminar la discriminación y el doble criterio para aquellos que se han quedado sistemáticamente atrás.

El mundo fue testigo de los masivos impactos negativos de COVID-19 y la crisis que ha generado: desde la privación de derechos a la vida familiar, la educación, la vivienda, el empleo, hasta la violencia doméstica y sexual. Lamentablemente, esto es lo que las personas afectadas por la enfermedad de Hansen (también conocida como lepra) han estado experimentando durante miles de años. Innumerables personas con enfermedad de Hansen fueron aisladas de las sociedades, a pesar de que nunca hubo pruebas que respaldaran esas políticas. Sus hijos fueron separados de los padres, y a menudo institucionalizados. Y hasta hoy, permanecen olvidados, sin reparaciones o una vacuna.

Desde el comienzo de COVID-19, he recibido numerosos informes sobre un impacto desproporcionadamente negativo en las personas afectadas por la enfermedad de Hansen en muchos países, sobre los cuales escribí una carta abierta a los gobiernos. Los datos pertinentes sobre la crisis humanitaria y sanitaria ni siquiera se recopilan ni se ponen a disposición. Ante la falta de respuestas de los gobiernos, las personas afectadas por la enfermedad de Hansen han estado a la primera fila de la ayuda de emergencia a sus comunidades.  Sin duda podemos esperar crecientes disparidades y un retroceso en el control de la lepra, la transmisión y la prevención de las discapacidades, así como en el empeoramiento de un nivel de vida ya extremadamente precario.

Estos dobles criterios en la respuesta a la crisis de COVID-19, junto con la amenaza múltiple de los problemas mutuamente exacerbantes, han estado amenazando el derecho a la vida de las personas afectadas por la enfermedad de Hansen. Es profundamente preocupante que desde mediados de 2020, las personas que han sido diagnosticadas con enfermedad de Hansen no hayan recibido medicamentos esenciales, (a saber, la terapia multifdroga – MDT –, que se distribuye gratuitamente) para tratar la enfermedad, en algunos países, incluso en Brasil. Según los datos de OMS, Brasil es el país con las tasas de infección más altas por cada 100.000 habitantes (aproximadamente 28.000 nuevos casos al año) y con un número significativo de personas diagnosticadas con discapacidades físicas ya irreversibles.

Las discapacidades físicas causadas por la enfermedad de Hansen se pueden prevenir con un diagnóstico oportuno y un tratamiento adecuado con MDT. La enfermedad de Hansen es curable con MDT y una vez iniciado el tratamiento la enfermedad ya no puede transmitirse. Sin embargo, el doble criterio en las respuestas institucionales a la enfermedad de Hansen y la estigmatización asociadas con la enfermedad son un obstáculo para poner fin a la transmisión. La escasez de MDT está agravando tanto las discapacidades como la transmisión y causando un gran sufrimiento.

La historia de la enfermedad de Hansen muestra lo costosas que pueden ser la discriminación y las desigualdades, no sólo para los pacientes individuales y sus familiares, sino también para las sociedades en su conjunto. Varias de las violaciones e intersecciones bien conocidas por las personas afectadas por la enfermedad de Hansen – el miedo de la sociedad, la estigmatización, el aislamiento y su impacto de la salud mental, la segregación, la violencia de género, el racismo, la xenofobia, entre otros - están siendo descubiertas por la actual pandemia. Hay mucho que aprender de la historia de la lucha de las personas afectadas por la enfermedad de Hansen contra todas estas formas de violencia y discriminación. Y la lección principal es que no hay reconstruir mejor si los Estados no ponen a los que quedan atrás en el centro de la recuperación".

FINAL

La Sra. Alice Cruz es la Relatora Especial de la ONU sobre la eliminación de la discriminación contra las personas afectadas por la lepra y sus familiares. Fue nombrada en noviembre de 2017 por el Consejo de Derechos Humanos. La Sra. Cruz trabajó como Profesora Externa en la Facultad de Derecho de la Universidad Andina Simón Bolívar – Ecuador y en varias universidades portuguesas como investigadora en salud y derechos humanos, en particular la enfermedad de Hansen. Participó en la elaboración de las Directrices de la OMS para Fortalecer la Participación de las Personas Afectadas por la Enfermedad de Hansen en los Servicios de la Enfermedad de Hansen. Ha investigado y escrito sobre el tema de la eliminación de la enfermedad de Hansen y el estigma que se le atribuye y ha interactuado con diversas partes interesadas, incluso las personas afectadas por la enfermedad de Hansen.

Los Relatores Especiales forman parte de lo que se conoce como los Procedimientos Especiales del Consejo de Derechos Humanos. Procedimientos Especiales, el mayor órgano de expertos independientes en el sistema de derechos humanos de las Naciones Unidas, es el nombre general de los mecanismos independientes de investigación y seguimiento del Consejo que abordan situaciones específicas de los países o cuestiones temáticas en todas las partes del mundo. Los expertos en Procedimientos Especiales trabajan de forma voluntaria; no son personal de las Naciones Unidas y no reciben un salario por su trabajo. Son independientes de cualquier gobierno u organización y sirven en su capacidad individual.

 

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/f9fbb2a6-63cd-4618-9dc9-b785588fdcb7n%40googlegroups.com.

Saturday, January 30, 2021

Fw: (LML) Rifampicin warning


 

 


Leprosy Mailing List – January 30 ,  2021

 

Ref.:  (LML) Rifampicin warning

 

From:  Wim van Brakel, Amsterdam, the Netherlands

 

Hallo Pieter,


I would like to add one comment concerning the message from Dr Ruth Butlin. The interim advice from the ILEP Technical Commission (ITC) was not meant to be a warning, but a response to concerns raised about the nitrosamine impurities discovered in rifampicin in 2020. The intention is to put people's minds at ease.


The key message is that the level of these impurities is still very low, especially considering the limited number of doses of rifampicin consumed during MDT and particularly as part of SDR-PEP. The concerned authorities (WHO, US Food and Drug Administration and the European Medicine Agency) agree that there is no reason to discontinue MDT or PEP programmes. The nitrosamine impurities are being investigated further by these agencies and manufacturers have been instructed to test all rifampicin batches that are currently produced. So far, all but one of these test results show that the impurity levels are below the maximum level recommended by the US FDA (5ppm).


The ITC will continue to follow the developments closely and in close collaboration with WHO GLP and Novartis. The most recent news indicates that the production of rifampicin without elevated levels of nitrosamine is likely to commence sometime around mid-2021.


Kind regards,


Wim van Brakel

Chair ILEP Technical Commission



Wim van Brakel
Medical Director

W.vanBrakel@nlrinternational.org
P.O. Box 95005, 1090 HA Amsterdam, The Netherlands
www.nlrinternational.org   |  Twitter: @NLR_NoLeprosy


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/bc6ba59a-d2b2-4695-9420-837d49f3d63en%40googlegroups.com.

Friday, January 29, 2021

Fw: (LML) clofazimine and QT prolongation


 

 

Leprosy Mailing List – January 29,  2021

 

Ref.:  (LML) clofazimine and QT prolongation

 

From:  Ruth Butlin, London, UK

 

 

Dear Pieter,


I have heard that clofazimine can cause a significant degree of QT prolongation, especially when in combination with other drugs which have this propensity.


I wonder if this is only a significant clinical problem with high dose clofazimine (as used for ENL cases), not with the doses used in standard MDT?


How frequent is the problem in people who do not have a predisposing cardiac abnormality?


I wonder, should we consider taking ECGs before starting high dose clofazimine? This would be difficult to implement in many leprosy-endemic regions.


I would be grateful if anyone can point me to published evidence on this adverse effect of clofazimine. Thank you.

 

Yours faithfully,


C Ruth Butlin


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/4edffacf-e56e-4eb9-bfe6-bcdf5270a240n%40googlegroups.com.

Thursday, January 28, 2021

Fw: (LML) Rifampicin warning


 

Leprosy Mailing List – January 28,  2021

 

Ref.:  (LML) Rifampicin warning

 

From:  Ruth Butlin, London, UK

 

Dear Colleagues,

 

I would like to bring, to attention of readers of LML, this warning from ILEP about possible contamination of rifampicin by nitrosamine.

I saw it on a link from the GPZL newsbulletin received on 27.1.21

Yours faithfully, C Ruth Butlin



Interim advice on the use of rifampicin for post-exposure prophylaxis (PEP)

6 January, 2021 | ILEP Technical Commission:

 

Interim advice on the use of rifampicin for post-exposure prophylaxis (PEP), in light of recent information on nitrosamine impurities in rifampicin

A number of different problems have affected the supply of rifampicin and MDT to countries this year. The most recent of these has been the discovery of impurities (nitrosamines) in rifampicin that are assumed to pose a health risk if high cumulative doses are consumed. Certain nitrosamines were found to increase the risk of cancer in long-term animal studies, although direct evidence of harm is still lacking. Nitrosamines are found in many products, e.g. various types of food, especially in baked or fried food, drinking water, tobacco smoke and rubber products. The particular impurity in rifampicin concerns a nitrosamine called MNP (1-methyl-4-nitrosopiperazine). This is most likely a by-product in the production of rifampicin. This compound would need to be washed out of the final drug product. Although this issue was only discovered recently due to new screening of drugs for nitrosamine recommended by WHO and other authorities, it is considered likely that nitrosamines have been present in rifampicin for years. Because this compound appears to be common to all manufacturers, they must all come up with ways to improve their processes to reduce or eliminate the impurities.

With regard to nitrosamine, it is the cumulative dose that is important, suggesting that it is not a serious issue for treatment with MDT or its use as PEP, in which the total 'lifetime dose' of rifampicin is low, when compared with treatment for TB (except in countries such as the US, where MDT with daily rifampicin is given for 2 years). Both the US Food & Drug Administration (FDA) and the European Medicines Agency (EMA) have indicated that treatment for both TB and leprosy should continue, while the manufacturing process is revised to minimize these impurities.¹ However, no statements have been made about rifampicin use for chemoprophylaxis, while this issue obviously has an impact on all PEP programmes around the world.

The FDA currently recommends a daily limit of 5 ppm, which is has been temporarily raised from the original very conservative threshold of 0.16 ppm. Both these limits have longer-term rifampicin use in view, such as in treatment of TB where a 600mg dose of rifampicin is given daily for 6 months (in adults). We therefore consider the potential health risk posed by a single dose of rifampicin to be negligible. However, since SDR-PEP is given to healthy individuals, ethics would demand that all known risks to health be minimised.

Similar issues are being addressed in the TB field, where combination preventive treatment is used for children (age 2-5) and persons living with HIV, comprising either a 3-month regimen of daily rifampicin and isoniazid, or a 3-week, 12-dose combination of isoniazid and rifapentine (3-HP). A different nitrosamine has been found in rifapentine (1-cyclopentyl-4-nitrosopiperazine (CPNP)). Similar to rifampicin, an FDA statement recommends that TB treatment containing rifapentine (mostly second line treatment) be continued. A cut-off level of nitrosamine impurities has been specified below which rifapentine can be used, as for MNP in rifampicin. A large TB consortium conducting the implementation studies of the 3-HP regimen has decided to continue with the distribution using the same cut-off level as specified for treatment, considering the cumulative dose of CPNP ingested in 12 doses to pose a negligible risk.

The WHO Global TB Programme has taken up the issue of nitrosamine impurities in rifampicin and rifapentine with the WHO Pre-qualification (PQ) Team – Medicines (a global quality assurance programme for medicines). WHO PQT/MED is pursuing this with all producers of API and finished product. This is still ongoing and further guidance will be provided when this is completed. ITC is now connected to this conversation to ensure that the use of rifampicin for SDR-PEP is also considered. The Global Leprosy Programme has advised that any actions or recommendations from our side should be aligned with those of the WHO Global TB Programme (GTB) to avoid undermining their position in the implementation of the 3-HP prophylactic regimen. We are now in conversation with the WHO GTB and WHO PQT/MED and they indicated they would be happy to tackle the rifampicin issue for TB and leprosy jointly. WHO PQT/MED is pursuing the issue of nitrosamine contamination of rifampicin with all producers of 'active pharmaceutical ingredient' and finished product. This is still ongoing and further guidance will be provided when this is completed. The GTB advised that "it will be prudent to wait until the PQ analyses are completed before having a firm position on this."

The EMA is currently conducting further investigations and a risk assessment of the nitrosamine impurities and will give updated advice from time to time. The EMA has a deadline of March 31st, 2021, for providing this risk analysis for chemical medicines.

In view of the above, we will wait with any recommendations regarding SDR-PEP distribution until the various ongoing investigations and the conversation with the Global TB and PQ programmes have concluded and their position has become clear.

Where ILEP is involved in the distribution of MDT or rifampicin, we recommend that only batches be purchased and/or used that have maximum nitrosamine levels below 5ppm per day as recommended by the US FDA. Recent samples from currently available batches of MDT were tested and found to have levels of nitrosamine under this limit, so if testing is not possible at present, current stocks of MDT are deemed to be safe.

Given the challenges in MDT supply, MDT availability and supply should be taken into account when planning or implementing PEP programmes. There are two main considerations:

  1. When there is a shortage of MDT, any available rifampicin may need to be used for treatment of leprosy patients, rather than for chemoprophylaxis among contacts.
  2. Whenever active case-finding efforts are undertaken, including contact examinations, the availability of treatment for any new cases identified must be ensured (preferably MDT). MDT is essential and safe for treatment of leprosy patients. Novartis/Sandoz has resumed producing and releasing MDT batches that have been tested for nitrosamines and found to be below the safety level currently recommended by the US FDA.

Since screening for nitrosamine has not been standard in the quality control process of rifampicin, we recommend that this be included as part of all future quality control testing of rifampicin.

We recommend that ILEP offices do everything in their power to facilitate nitrosamine testing (MNP specifically) of rifampicin already available in their country that is used for SDR-PEP. WHO PQT/MED requested all manufacturers/suppliers of rifampicin or its active ingredient to undertake a risk evaluation for nitrosamine impurities by end of 2020.² Therefore, such testing should be done by each company producing rifampicin and/or by the national drug authority in charge of monitoring the quality of drugs.

 

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 

 

 

 

 

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/1cd031ce-eafe-4985-ada7-0dca93b03761n%40googlegroups.com.

Fw: (LML) Vlogs COVID-19 by Dr John Campbell

 


Leprosy Mailing List – January 28,  2021

 

Ref.:  (LML) Vlogs COVID-19 by Dr John Campbell

 

From:  Pieter AM Schreuder, Maastricht, the Netherlands

 

 

Dear colleagues,

 

 

Richard de Soldenhoff draw my attention to the vlogs about COVID-19 by Dr John Campbell: https://youtu.be/gRYFg-ZPs_U

Facts and pointed analyses. Highly recommended.

 

Best wishes,

 

 

Pieter AM Schreuder

 

 

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/623d5f49-df2d-4a7b-82a5-55a52cb17850n%40googlegroups.com.

Friday, January 22, 2021

Fw: (LML) A remote Hawaiian outpost and former leprosy colony free of corona

 


Leprosy Mailing List – January 22,  2021

 

Ref.:  (LML) A remote Hawaiian outpost and former leprosy colony free of corona

 

 

From:  Pieter AM Schreuder, Maastricht, the Netherlands

 

 

Dear colleagues,

 

Some positive news in these difficult times.

 

Best wishes,

 

Pieter AM Schreuder

 

 

 

"A remote Hawaiian outpost and former leprosy colony

 January 22, 2021  Pehal News Team 



According to Hawaii health officials, a resident,  who had travelled outside Kalawao County in December, tested positive for corona, ending Kalawao County's spectacular run being corona free. The person involved adopted the county's self-quarantine rule upon arrival, and prevented what may have been a disastrous outbreak.

 

The undeniable fact that Kalawao County remained virus-free can partially be attributed to geography. Located on the small island of Molokai, its single city, Kalaupapa, can solely be reached by mountaineering down 1,600-foot cliffs, catching a uncommon flight on a small aircraft or making an arduous three-mile trek by mule. That seclusion additionally explains its painful historical past: In 1865, Hawaii determined that anybody identified with leprosy — now often called Hansen's illness — could be exiled there for all times.

 

In 1969, after a treatment for Hansen's illness was launched, Hawaii lastly overturned the necessary quarantine coverage. But some sufferers opted to stay on the island as a result of they'd grown accustomed to the approach to life and feared the stigma that they could face elsewhere. Though a lot of the Kalawao County is now a national park, roughly a dozen survivors nonetheless reside there in the present day, within the care of the state.

 

"Our patients are, on average, 86 years old. They all have other health issues, so they're at extreme high risk for covid mortality," Baron Chan, the department chief for Hansen's illness on the Hawaii Department of Health, told KHON in October.

 

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/3bec1faf-99ac-4d67-880b-e0196b0ea3e9n%40googlegroups.com.

Friday, January 15, 2021

Fw: (LML) WHO will formally launch its new road map for NTDs on 28 January 2021

 


Leprosy Mailing List – January 15,  2021

 

Ref.:  (LML) WHO will formally launch its new road map for NTDs on 28 January 2021

 

From:  Henk Eggens, Santa Comba Dão, Portugal

 _____________________________________________________________________________________


Dear Pieter,

 

WHO, 11 January 2021, Neglected tropical diseases:


WHO to formally launch new road map for neglected tropical diseases for the next decade ( https://www.who.int/news/item/11-01-2021-neglected-tropical-diseases-who-to-formally-launch-new-road-map-for-next-decade )  on 28 January 2021.


Registration for the Zoom webinar (  https://who.zoom.us/webinar/register/WN_0-XfZsDjQTSpBsVaTIAS0Q ) is open for the virtual launch which comprises a 2-hour programme with the participation of Heads of State, Ministers of Health of several countries, WHO Director-General and Regional Directors and partner organizations.

The launch virtual campaign will start on 18 January with curated themes, roadmap-specific shareable content to amplify messages. These include video clips on various shifts of the new road map, the 2030 targets and potential challenges.

 

Relevant links:


1. Global consultation of National Leprosy Programme managers, partners and affected persons on Global Leprosy Strategy 2021–2030
Report of the virtual meeting 26–30 October 2020 https://www.who.int/publications/i/item/9789290228226

2. Global Leprosy Strategy 2021–2030; Overview by Erwin Cooreman MD MSc DTM&H, Team Leader, Global Leprosy Programme WHO
  https://www.who.int/docs/default-source/ntds/leprosy/global-consultation-on-global-leprosy-strategy-2021-2030/06-global-leprosy-strategy-overview.pdf

 

---
Henk Eggens

(henk.eggens@gmail.com)

____________________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/3e2ea24e-dd57-426c-9084-a130708f0aafn%40googlegroups.com.

Tuesday, January 12, 2021

Fw: (LML) Dr Elisabeth Duncan


 

Leprosy Mailing List – January 12,  2021

 

Ref.:  (LML) Dr Elisabeth Duncan

 

From:  Sunil Deepak, Schio, Italy

____________________________________________________________________________________

 

Dear Pieter,

 

The second edition of the Textbook of Leprosy published by Springer is being prepared.

 

I am writing to you to ask for the LML readers in getting some information about Dr Elisabeth Duncan who used to be at ALERT and had written one of the chapters in the first edition of this book.

 

If anyone knows about her or can help in contacting her please do write to me.

 

Thanks in advance,

 

Dr Sunil Deepak

Schio (VI), Italy

Email: sunil.deepak@gmail.com

______________________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/cce85e2b-e9a8-4d36-be8c-5d314b997296n%40googlegroups.com.

Thursday, January 7, 2021

Fw: (LML) MDT duration and ENL neuritis risk


 


Leprosy Mailing List – January 7,  2020

 

Ref.:  (LML) MDT duration and ENL neuritis risk

 

 

From:  Joel Almeida, London and Mumbai

 

 

Dear Pieter,

 

Front-line clues allow rapid improvements in the quality and efficacy of interventions. At the start of a new decade, we can focus on what demonstrably works and discard what does not. This reduces suffering for our patients and our people.  

 

Happy New Year to all,

 

Joel Almeida

= = = = =

 

 

MDT duration and ENL neuritis risk

 

Introduction

 

ENL (Erythema Nodosum Leprosum) is an extremely painful and distressing "reaction" condition often involving many organ systems. It occurs most commonly in highly bacillated types of HD (leprosy). 

 

Does the duration of MDT (multi-drug therapy) affect the risk of ENL neuritis among LL (lepromatous) patients? More specifically, does withdrawing MDT after 12 months have any impact on the risk of ENL neuritis subsequently? 

 

Methods

 

Comparison was made by Balagon, Gelber et al between one-year MDT and two-year MDT.(1) 58 LL patients given one-year MDT were compared to 139 LL patients given two-year MDT. 

 

Months 13 to 24 after the start of MDT are of particular interest. The one-year MDT group had no MDT during months 13 to 24, but the two-year MDT group did. 

 

Patients with signs of reaction were examined weekly or fortnightly.  ENL reactions were considered severe if there were  more than 20 ENL skin lesions or if papulonodules of ENL were associated with either severe joint pains, edema, high fever, other constitutional signs and symptoms of iritis, laryngitis, orchitis, and other organ involvement. Any neuritis was noted. Neuritis was defined as pain associated with swelling and tenderness of a nerve.

 

The incidence rate of ENL reactions with neuritis in the one-year MDT group during months 13 to 24 after the start of MDT can be compared to that in the two-year MDT group. The Incidence Rate Ratio is used.

 

Results

 

The results are shown in the Figure.

 

 

 

The Figure. (see attached file) The one-year MDT group showed a 600% increase in the risk of ENL with neuritis compared to the two-year MDT group, during months 13 to 24 after the start of MDT.

 

Discussion

 

It would be good to continue MDT beyond 12 months in LL patients. Otherwise they are needlessly subjected to a greatly multiplied risk of the painful, swollen and tender nerves found in the neuritis of ENL "reactions". 

 

Reference

 

1.    Balagon MVF, Gelber RH, Abalos RM, Cellona RV. Reactions following completion of 1 and 2 year multidrug therapy (MDT) Am J Trop Med Hyg  2010 Sep;83(3):637-44. doi: 10.4269/ajtmh.2010.09-0586

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/c9e30ac9-8c91-4cfb-a8dc-681b277870fen%40googlegroups.com.

Virus-free. www.avast.com

Wednesday, January 6, 2021

Fw: (LML) New publications on leprosy. January 2021

 

 
Leprosy Mailing List – January 5,  2021

 

Ref.:  (LML) New publications on leprosy. January 2021

 

From:  Annemiek Akerboom, Amsterdam, the Netherlands

 __________________________________________________________________________________

 


  Dear colleagues,


Infolep wishes you a healthy, joyful and prosperous new year!



Many of us look back at a challenging year. A year in which we faced uncertainty, fear, restrictions and losses. But 2020 has also shown us that we are resilient, innovative and cooperative. A lot of research has been conducted on leprosy and COVID-19 and beautiful initiatives emerged to support each other and especially marginalized populations. A crisis like the COVID-19 pandemic disproportionally affects marginalized individuals, such as people affected by leprosy, and more clearly exposed the impact of stigma. We truly hope 2021 will be the year in which we will build back better.

This new year kick-starts with an exciting month, as we will celebrate World Leprosy Day on 30 January and the WHO will launch the NTD Roadmap on 28 January.

Below you will find the list with new publications on leprosy and interesting events. Feel free to contact me to receive full-text versions if these cannot be found through the Infolep portal. Also, I would be happy to assist you with literature searches.


Thank you for your interest and support in 2020. We look forward to best serve your information needs and collectively work towards a world without leprosy in the coming years.

Warm regards,

Anniek Akerboom

Infolep Coordinator
www.leprosy-information.org
a.akerboom@infolep.org



 

 


Highlighted

 



World Leprosy Day
31 Jan 2021
Learn more


Interim Advice on the use of Rifampicin for post-exposure prophylaxis (PEP), in light of recent information on nitrosamine impurities in rifampicin
ILEP Technical Commission. 2020;
Learn more


Thirteenth meeting of the Strategic and Technical Advisory Group for Neglected Tropical Diseases, 15–17 September 2020
World Health Organization. 2020;
Learn more

 


Leprosy & COVID-19

 



 



Severe Type 2 leprosy reaction with COVID-19 with a favourable outcome despite continued use of corticosteroids and methotrexate and a hypothesis on the possible immunological consequences.
Saxena S, Khurana A, B S, et al. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2020; 
Learn more

 



 



New publications

 



 



The adverse drug effects of dapsone therapy in leprosy: a systematic review
Hilder R, Lockwood D. Leprosy review. Lepra. 2020; 91 (3) : 232-243. 
Learn more

Hansen's Disease: differences in clinical presentation among Latin American and South East Asian born patients identified in Los Angeles County, California (1995–2016)
Croker C, Phommasith J, Jerskey R, et al. Leprosy review. Lepra. 2020; 91 (3) : 244-254. 
Learn more

Leprosy in a prison population: A new active search strategy and a prospective clinical analysis.
Filho F, Santana J, de Almeida R, et al. PLoS neglected tropical diseases. 2020; 14 (12) : e0008917. 
Learn more

Assessing the prospect of a common health-related stigma reduction response: Cross-perspectives of people living with stigmatised health conditions in Indonesia.
Rai S, Syurina E, Peters R, et al. Global public health. 2020; 
Learn more

Leprosy post-exposure prophylaxis: innovation and precision public health.
Moraes M, Düppre N. The Lancet. Global health. 2021; 9 (1) : e8-e9. 
Learn more

Why can't we control Morbus Hansen?
Naafs B. info Hansen. 2020; 
Learn more

Polymorphisms in mitochondrial ribosomal protein S5 (MRPS5) are associated with leprosy risk in Chinese.
Xing Y, He J, Wen Y, et al. PLoS neglected tropical diseases. 2020; 14 (12) : e0008883. 
Learn more

Single-Nucleotide Polymorphisms in Genes Predisposing to Leprosy in Leprosy Household Contacts in Zhejiang Province, China
Shen Y, Long S, Kong W, et al. Pharmacogenomics and Personalized Medicine. Informa UK Limited. 2020; 
Learn more

Analysis of the Myeloid-Derived Suppressor Cells and Annexin A1 in Multibacillary Leprosy and Reactional Episodes
Damazo AS, Silva SFD, Cavalcante LRDS, et al. Research Square. 2020; 
Learn more

Misdiagnosis of leprosy in Brazil in the period 2003 - 2017: spatial pattern and associated factors.
Neves K, Nobre M, Machado L, et al. Acta tropica. 2020; 
Learn more

The Dermlep Study Part 2: Results of a Nation-Wide Survey of Dermatologists' Access to Quality Leprosy Services at their Clinics and Hospitals in India.
Rao NP, Rathod S, Suneetha S, et al. Indian dermatology online journal. 2020; 11 (6) : 895-903. 
Learn more

Gandhi's Evolving Discourse on Leprosy
Kakar S. Palgrave Studies in the History of the Media. Springer International Publishing. 2020;
Learn more

Relationship between Plantar Pressure and Sensory Disturbance in Patients with Hansen's Disease-Preliminary Research and Review of the Literature.
Tashiro S, Gotou N, Oku Y, et al. Sensors (Basel, Switzerland). 2020; 
Learn more

Synthetic Phenolic Glycolipids for application in diagnostic tests for leprosy.
van Dijk HJ, van Hooij A, Groot ML, et al. Chembiochem : a European journal of chemical biology. 2020;
Learn more

Functional biomarker signatures of circulating T-cells and its association with distinct clinical status of leprosy patients and their respective household contacts.
Marçal P, Gama R, de Oliveira L, et al. Infectious diseases of poverty. 2020; 9 (1) : 167. 
Learn more

Why do Leprosy patients default treatment; Evidence from Sri Lanka
Arnold M. International Journal of Progressive Sciences and Technologies. 2020; 23 (2) : 654-659. 
Learn more

HARP: a database of structural impacts of systematic missense mutations in drug targets of Mycobacterium leprae.
Vedithi S, Malhotra S, Skwark M, et al. Computational and structural biotechnology journal. 2020; 
Learn more

Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach.
Cruz R, Bührer-Sékula S, Penna G, et al. Anais brasileiros de dermatologia. 2018; 93 (3) : 377-384.
Learn more

Effectiveness of the retreatment of patients with multibacillary leprosy and episodes of erythema nodosum leprosum and/or persistent neuritis: a single-center experience.
Lastória J, Putinatti M, de Almeida T, et al. Anais brasileiros de dermatologia. 2018; 93 (2) : 181-184. 
Learn more

Endocrinological Testicular Dysfunction in Patients with Lepromatous Leprosy and the Impact of Disease on Patient's Quality of Life.
Mohta A, Agrawal A, Sharma P, et al. Indian dermatology online journal. 2020; 11 (6) : 959-964. 
Learn more

Hanseniasis in the municipality of Western Amazon (Acre, Brazil): are we far from the goal of the World Health Organization?: Hansen and Western Amazon.
Araújo F, Abreu L, Laporta G, et al. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. 2020; 
Learn more

Epidemiological profile and tendency of leprosy in people younger than 15 years.
Santos Á, Costa A, de Souza J, et al. Revista da Escola de Enfermagem da U S P. 2020; 
Learn more

Risk Factors Related to the Events of Leprosy in Children age 5-14 Years in City of Sorong West Papua
Maryen Y, Parlaungan J, Samaran E, et al. Medico Legal Update. 2020; 20 (4) : 2160-2167. 
Learn more

Spectrum of Inborn errors of immunity in a cohort of 90 patients presenting with complications to BCG vaccination in India.
Yadav R, Dalvi A, Gupta M, et al. Scandinavian journal of immunology. 2020;
Learn more

Empowerment Based on Collaborative Governance in Leprosy Patients In Central Java
Imam Al Hafis R, Larasati E, Warsono H, et al. 6th International Conference on Social and Political Sciences (ICOSAPS 2020). 2020; 
Learn more

La influencia del poder colonial sobre la población y la naturaleza determinaron los asentamientos de la enfermedad de Hansen en Surinam.
Menke H, Pieters T, Menke J. Revista de Leprología. 2020; 32 (6) : 411-439. 
Learn more

Porcentajes variables de casos de lepra paucibacilar en la notificación global de casos de lepra.
Butlin R, Lockwood DNJ. Revista de Leprología. 2020; 32 (6) : 441-449. 
Learn more

 



 



Interesting events

 



 



ISNTD Connect Webinar: Disease management, disability and inclusion: disability inclusion to achieve the NTD Roadmap targets
03 Dec 2020 | Recording
Watch it here

ISNTD Connect Webinar: Health Technologies for NTDs: Accelerating Research & Development for Impact
17 Dec 2020 | Recording
Watch it here

Sasakawa Health Foundation's Webinar Series 'Issues in Leprosy amid the Coronavirus Pandemic':

WHO NTD Roadmap launch
28 Jan 2021 | Online
The link to register will be provided soon

World NTD Day
30 Jan 2021

World Leprosy Day in India
30 Jan 2021

World Leprosy Day
31 Jan 2021

 



 



 



 



Websites & Services

 



 




Info Hansen - A innovative hub for knowledge sharing about Hansen's Disease
https://www.infohansen.org/

ALLF - Official website of the Association des Léprologues de Langue Française
https://allf.medicalistes.fr/

LML - Leprosy Mailing List - a free moderated email list that allows all persons interested in this theme to share ideas, information, experiences, and questions.
https://groups.google.com/forum/#!forum/leprosymailinglist

InfoNTD - Information on cross-cutting issues in Neglected Tropical Diseases (NTDs)
https://www.infontd.org/




 

 



 



Newsletters & Journals

 



 



ILEP newsletter archive: ilepfederation.org/news-events/#archive
 
GPZL newsletter archive: zeroleprosy.org/newsletter-archive

Hansenologia Internationalis: www.ilsl.br/revista/atual.php

Indian Journal of Leprosy: www.ijl.org.in/index.html

Leprosy Review: leprosyreview.org
Leprosy Review Repository (1928-2001): leprev.ilsl.br/arquivo.php

Fontilles Revista de Leprología: www.leprosy-information.org/resource/revista-de-leprologia

 



 



GDPR & the Infolep newsletter

 



 




New EU data protection regulations came into force on 25 May 2018. We have been reviewing our practices with regard to the GDPR, including our privacy statement and mailing list. Infolep sends out monthly e-mails to its subscribers with an overview of recent publications on leprosy. The purpose of this activity is to keep subscribers up to date. Infolep will only process the data we have (names, email addresses) for the purpose of sending you the newsletter. We take your security seriously and will never share your contact details with anyone else. We hope the content from the Infolep newsletter is useful to you, but you can update your preferences or unsubscribe from this list at any time.



 

 



 


 






Copyright © 2020 Infolep, All rights reserved.
You are receiving this mail because you opted in at our website

Our mailing address is:
Infolep
Wibautstraat 137-k
Amsterdam, 1097 DN
Netherlands

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list

______________________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/5d948d4a-c5d0-4e77-875d-3a5b4d7615f6n%40googlegroups.com.